|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2003-11-7
|
|
pubmed:abstractText |
Even within the normal range, aldosterone levels are linked to end-organ toxicity and mortality in patients with hypertension. Treatment with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers does not sufficiently reduce plasma aldosterone levels.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0149-2918
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2388-404
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14604739-Adolescent,
pubmed-meshheading:14604739-Adult,
pubmed-meshheading:14604739-Aged,
pubmed-meshheading:14604739-Aldosterone Antagonists,
pubmed-meshheading:14604739-Antihypertensive Agents,
pubmed-meshheading:14604739-Dose-Response Relationship, Drug,
pubmed-meshheading:14604739-Drug Therapy, Combination,
pubmed-meshheading:14604739-Female,
pubmed-meshheading:14604739-Humans,
pubmed-meshheading:14604739-Hypertension,
pubmed-meshheading:14604739-Male,
pubmed-meshheading:14604739-Middle Aged,
pubmed-meshheading:14604739-Spironolactone
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
|
|
pubmed:affiliation |
Department of Medicine, University of Calgary, Calgary, Alberta, Canada. ellen.burgess@calgaryhealthregion.ca
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
